Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 34.5%

Gross margin was 34.5% in Q1 FY2026, up 38.2 pp from a year earlier. On a trailing-twelve-month basis it was 37.1%, up 20.9 pp year over year. Over 3 fiscal years it narrowed by 6.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
34.5%-3.0 pp QoQ
Last fiscal yearDec 2025
31.7%+7.5 pp YoY
LTMMar 2026
37.1%+20.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+38.2 pp——
1 year+7.5 pp——
3 years-6.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
31.7%
Year-over-year change
+7.5pp

Gross Margin vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's LTM Mar 2026 gross margin of 37.1% is the lowest of the 3 companies compared; the peer median is 53.4%.
  • Its year-over-year change of +20.9 pp is the highest of 3, against a peer median of -6.6 pp.
  • Over three fiscal years its change of -6.5 pp compares with a peer median of +1.9 pp.
PACB Competitors Peer median
Gross Margin for PACB and competitors
Company Period LTM level YoY 3-year change
ILMNIllumina, Inc.LTM Jun 202666.8% -0.3 pp+1.9 pp
QSIQuantum-Si incorporatedLTM Mar 202640.0% -12.8 pp—
PACBPacific Biosciences of California, Inc.LTM Mar 202637.1% +20.9 pp-6.5 pp
Peer median (excluding PACB) 53.4%-6.6 pp+1.9 pp

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.51M128.3M200.52M154.01M160.01M
Cost of Revenue71.65M79.27M147.74M116.73M109.33M
Gross Profit58.86M49.04M52.78M37.28M50.67M
Gross Margin45.1%38.2%26.3%24.2%31.7%
Research & Development112.9M193M187.17M134.92M97.31M
Selling, General & Admin124.12M160.85M169.82M175.02M141.49M
Operating Expenses269.3M356.23M387.25M511.6M608.24M
Depreciation & Amortization11.59M17.32M32.69M53.35M504.91M
EBITDA(250.76M)(282.24M)(271.13M)(242.77M)(34.2M)
EBITDA Margin-192.1%-220.0%-135.2%-157.6%-21.4%
Operating Income(210.44M)(307.2M)(334.47M)(474.31M)(557.56M)
Operating Margin-161.2%-239.4%-166.8%-308.0%-348.5%
Interest Income00000
Interest Expense12.53M14.69M14.34M13.41M6.95M
Other Income / Expenses(64.44M)(7.05M)16.31M164.78M11.5M
Income Before Tax(274.87M)(314.25M)(318.16M)(309.54M)(546.06M)
Pre-Tax Margin-210.6%-244.9%-158.7%-201.0%-341.3%
Income Tax Expense(93.65M)0(11.42M)316K318K
Net Income(181.22M)(314.25M)(306.74M)(309.85M)(546.38M)
Net Margin-138.9%-244.9%-153.0%-201.2%-341.5%
EPS (Basic)(0.89)(1.40)(1.21)(1.13)(1.82)
EPS (Diluted)(0.89)(1.40)(1.21)(1.07)(1.82)
Weighted Avg Shares203.62M224.55M253.63M274.49M299.96M
Weighted Avg Shares (Diluted)204.14M224.55M253.63M288.37M299.96M

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.